Your browser doesn't support javascript.
loading
High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.
Chow, S; Galvis, V; Pillai, M; Leach, R; Keene, E; Spencer-Shaw, A; Shablak, A; Shanks, J; Liptrot, T; Thistlethwaite, F; Hawkins, R E.
Afiliação
  • Chow S; The Christie NHS Foundation Trust, Manchester, UK.
  • Galvis V; The Christie NHS Foundation Trust, Manchester, UK.
  • Pillai M; The Christie NHS Foundation Trust, Manchester, UK.
  • Leach R; The Christie NHS Foundation Trust, Manchester, UK.
  • Keene E; The Christie NHS Foundation Trust, Manchester, UK ; The University of Manchester, Manchester, UK.
  • Spencer-Shaw A; The Christie NHS Foundation Trust, Manchester, UK.
  • Shablak A; The Christie NHS Foundation Trust, Manchester, UK.
  • Shanks J; The Christie NHS Foundation Trust, Manchester, UK.
  • Liptrot T; The Christie NHS Foundation Trust, Manchester, UK.
  • Thistlethwaite F; The Christie NHS Foundation Trust, Manchester, UK.
  • Hawkins RE; The Christie NHS Foundation Trust, Manchester, UK ; The University of Manchester, Manchester, UK ; The Christie Clinic, Manchester, UK.
J Immunother Cancer ; 4: 67, 2016.
Article em En | MEDLINE | ID: mdl-27777776
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article